Eli Lilly’s heart drug underwhelms with REWIND trial

pharmafile | June 11, 2019 | News story | Manufacturing and Production Eli Lilly, Trulicity, pharma 

Eli Lilly’s Trulicity (dulaglutide) reduced major cardiovascular events (MACE) by 12% versus placebo in adults with type 2 diabetes, according to the results of the REWIND trial.

The study of 9901 adults with type 2 diabetes looked at the glucagon-like peptide 1 receptor agonist Trulicity in combination with standard of care treatment in comparison to standard of care treatment combined with placebo.

While Lilly’s drug was effective in reducing major cardiovascular events the drug failed to meet the expectations of investors. According to MarketWatch Cowen analysts said investors had expected at least 20% risk reduction.

Shares in the Indianapolis-based firm fell by 2.4% in premarket trading.  

Louis Goss

Related Content


Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s …

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for …


Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials

Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C …

Latest content